stockrow
Friday 6 November 2026
Export PLRX’s income statement to Excel — free account
Pliant Therapeutics, Inc.
PLRX Healthcare Biotechnology
Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022.
- EPS
- +49.3%
- Free cash flow
- +68.6%
Quarter to June 2026, against a year earlier
0.81
0.01
−1.22%
Follow PLRX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
9.59 | 16.50 | 11.67 | 13.72 | |
Current Ratio |
9.90 | 16.89 | 12.00 | 13.93 | |
Net Debt/EBITDA |
6.66 | 8.10 | 8.33 | 7.69 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 11.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.15 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.57 | 0.96 | 0.75 | 0.80 | |
Capex/Depreciation |
0.13 | 0.15 | 0.00 | 0.20 | |
Interest Coverage |
— | — | (173.36) | (34.69) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.21) | (0.31) | (0.29) | (0.34) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.21) | (0.31) | (0.29) | (0.34) | |
Cash per Share |
2.55 | 2.77 | 3.11 | 3.94 | |
Shareholders Equity per Share |
2.37 | 2.67 | 2.95 | 3.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.37 | 2.67 | 2.95 | 3.26 | |
Free Cash Flow |
(12.78) | (19.13) | (17.79) | (20.92) | |
Working Capital |
146.66 | 164.57 | 180.08 | 227.96 | |
Capital Expenditures |
0.02 | 0.10 | 0.00 | 0.16 | |
Net Current Asset Value |
120.19 | 137.50 | 152.43 | 169.29 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.46 | 2.99 | 3.22 | 3.69 | |
Average Assets |
244.85 | 273.68 | 311.09 | 361.13 | |
Average Common Equity |
183.50 | 211.16 | 242.64 | 273.06 |
Columns are period end dates · fundamentals updated 26 Oct 2026